matthias

matthias Updated 

Bluebird has been a strong performer over the past year, which is now testing support. It probed its rising trendline support yesterday, and today dropped below that and tested its 100-day SMA. It seems that valuation concerns are the reason that the selling got underway a couple of days ago. But I haven't read anything negative about the strength of their...

matthias Updated 

QURE has been an extraordinarily strong performer since summer of last year, quintupling to $26+ a couple of weeks ago. The stock has since dropped a quick 20%. I plan to watch this tomorrow, and to buy on strength. My ultimate price target would be around $24, although I'd take first profit sooner. I like the fact that the company has a fair amount of cash in the...

matthias Updated 

Small development-stage biotech with ample cash and a partnership with Sanofi. Heart disease focus with initial compound entering Phase 3 trials. No immediate catalysts, but looks like a decent technical setup. Momentum leader that has quadrupled over the past year, currently in a meaningful pullback. Ideally would like to see it test the Feb lows and rising...

matthias Updated 

After a beat and raise on the 1/31 earnings report it popped initially, but then gradually gave it all up and dropped back to the $25/$26 consolidation level that first came into play in 9/17 following an impressive run. I think that valuation (fwd PE < 10) and the relatively long consolidation phase provide ample support at this level. This is not a fast mover,...